Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease.

Journal Article (Journal Article)

Infantile Krabbe disease (IKD) can be treated with hematopoietic cell transplantation (HCT) if done during the first weeks of life before symptoms develop. To facilitate this, newborn screening (NBS) has been instituted in 8 US states. An application to add IKD to the recommended NBS panel is currently under review. In this report, the outcomes of newborns with IKD diagnosed through NBS and treated with HCT are presented. The unique challenges associated with NBS for this disease are discussed, including opportunities for earlier diagnosis and streamlining treatment referrals. This is a retrospective review of six infants with IKD detected by NBS who were referred for HCT. The timing from diagnosis to HCT was examined, and both HCT and neurodevelopmental outcomes are described. Neurologic testing before HCT revealed evidence of active IKD in all infants. All underwent HCT between 24 and 40 days of age, were successfully engrafted, and are alive 30 to 58 months later (median, 47.5 months). All are gaining developmental milestones albeit at a slower pace than unaffected age-matched peers. Gross motor function is most notably affected. NBS for these patients enabled early access to HCT, the only currently available treatment of infants with IKD. All children are alive and have derived developmental and neurologic benefits from timely HCT. Long-term follow up is ongoing. Optimization of HCT and further development of emerging therapies, all of which must be delivered early in life, are expected to further improve outcomes of infants with IKD.

Full Text

Duke Authors

Cited Authors

  • Page, KM; Ream, MA; Rangarajan, HG; Galindo, R; Mian, AY; Ho, M-L; Provenzale, J; Gustafson, KE; Rubin, J; Shenoy, S; Kurtzberg, J

Published Date

  • May 10, 2022

Published In

  • Blood Adv

Volume / Issue

  • 6 / 9

Start / End Page

  • 2947 - 2956

PubMed ID

  • 35042231

Pubmed Central ID

  • PMC9092415

Electronic International Standard Serial Number (EISSN)

  • 2473-9537

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2021006094


  • eng

Conference Location

  • United States